SEC Info - Idexx Laboratories Inc/DE - ‘10-Q’ for 3/31/20

Idexx Laboratories Inc/DE – ‘10-Q’ for 3/31/20 – ‘EX-32.1’

On: Thursday, 4/30/20, at 5:27pm ET · For: 3/31/20 · Accession #: 874716-20-18 · File #: 0-19271

Document/Exhibit Description Pages Size 1: 10-Q Quarterly Report HTML 1.23M 2: EX-10.1 Material Contract HTML 31K 3: EX-10.2 Material Contract HTML 35K 4: EX-31.1 Certification -- §302 - SOA'02 HTML 35K 5: EX-31.2 Certification -- §302 - SOA'02 HTML 35K 6: EX-32.1 Certification -- §906 - SOA'02 HTML 30K 7: EX-32.2 Certification -- §906 - SOA'02 HTML 30K 21: R1 Cover Page HTML 80K 79: R2 Condensed Consolidated Balance Sheets HTML 142K 90: R3 Condensed Consolidated Balance Sheets HTML 41K (Parenthetical) 56: R4 Condensed Consolidated Statements of Income HTML 97K 20: R5 Condensed Consolidated Statements of Comprehensive HTML 69K Income 78: R6 Condensed Consolidated Statements of Comprehensive HTML 39K Income (Parenthetical) 89: R7 Condensed Consolidated Statements of Stockholders' HTML 62K Equity (Deficit) 51: R8 Condensed Consolidated Statements of Stockholders' HTML 29K Equity (Deficit) (Parenthetical) 22: R9 Condensed Consolidated Statements of Cash Flows HTML 113K 15: R10 Basis of Presentation and Principles of HTML 38K Consolidation 48: R11 Accounting Policies HTML 34K 80: R12 Revenue Recognition HTML 118K 67: R13 Acquisitions HTML 31K 16: R14 Share-Based Compensation HTML 44K 49: R15 Credit Losses HTML 37K 81: R16 Inventories HTML 38K 68: R17 Leases HTML 51K 17: R18 Other Current and Long-Term Assets HTML 55K 47: R19 Accrued Liabilities HTML 48K 100: R20 Debt HTML 93K 64: R21 Repurchases Of Common Stock HTML 49K 35: R22 Income Taxes HTML 31K 42: R23 Accumulated Other Comprehensive Income HTML 105K 101: R24 Earnings Per Share HTML 47K 65: R25 Commitments, Contingencies and Guarantees HTML 33K 36: R26 Segment Reporting HTML 145K 43: R27 Fair Value Measurements HTML 112K 99: R28 Hedging Instruments HTML 102K 66: R29 Subsequent Events (Notes) HTML 30K 71: R30 Accounting Policies (Policies) HTML 76K 84: R31 Revenue Recognition (Tables) HTML 60K 46: R32 Share-Based Compensation (Tables) HTML 40K 14: R33 Inventories (Tables) HTML 39K 70: R34 Leases (Tables) HTML 47K 83: R35 Other Current and Long-Term Assets (Tables) HTML 57K 45: R36 Accrued Liabilities (Tables) HTML 49K 13: R37 Debt (Tables) HTML 85K 69: R38 Repurchases of Common Stock (Tables) HTML 49K 85: R39 Accumulated Other Comprehensive Income (Tables) HTML 106K 61: R40 Earnings Per Share (Tables) HTML 47K 95: R41 Segment Reporting (Tables) HTML 143K 41: R42 Fair Value Measurements (Tables) HTML 101K 32: R43 Hedging Instruments (Tables) HTML 85K 60: R44 Accounting Policies (Details) HTML 44K 94: R45 Revenue Recognition (General Narrative) (Details) HTML 32K 40: R46 Revenue Recognition (Lease Revenue) (Details) HTML 29K 31: R47 Revenue Recognition (Extended Warranties and HTML 43K Post-Contract Support) (Details) 59: R48 Revenue Recognition (Remaining Performance HTML 73K Obligation) (Details) 96: R49 Revenue Recognition (SaaS Subscriptions) (Details) HTML 30K 87: R50 Revenue Recognition (Up-Front Customer Loyalty HTML 33K Programs) (Details) 72: R51 Revenue Recognition (Volume Commitment Programs) HTML 38K (Details) 26: R52 Revenue Recognition (Instrument Rebate Programs) HTML 33K (Details) 57: R53 Revenue Recognition (Reagent Rental Programs) HTML 40K (Details) 88: R54 Revenue Recognition (Disaggregation of Revenue by HTML 54K Major Product and Service Categories) (Details) 73: R55 Revenue Recognition (Disaggregation of Revenue by HTML 40K Principal Geographic Area, Based on Customers' Domiciles) (Details) 27: R56 Revenue Recognition (Costs to Obtain a Contract) HTML 38K (Details) 58: R57 Acquisitions Acquisitions (Details) HTML 44K 86: R58 Share-Based Compensation (Narrative) (Details) HTML 38K 74: R59 Share-Based Compensation (Assumptions Used) HTML 39K (Details) 28: R60 Credit Losses (Details) HTML 41K 38: R61 Inventories (Details) HTML 38K 97: R62 Leases (Maturities of Operating Lease Liabilities) HTML 56K (Details) 62: R63 Leases (Narrative) (Details) HTML 37K 29: R64 Leases (Supplemental Cash Flow Information) HTML 31K (Details) 39: R65 Other Current and Long-Term Assets (Schedule Of HTML 45K Other Current Assets) (Details) 98: R66 Other Current and Long-Term Assets (Schedule Of HTML 47K Other Long-term Assets) (Details) 63: R67 Accrued Liabilities (Schedule Of Accrued HTML 43K Liabilities) (Details) 30: R68 Accrued Liabilities (Schedule Of Other Long-term HTML 35K Liabilities) (Details) 37: R69 Debt Debt (Schedule of Current Senior Notes HTML 64K Outstanding) (Details) 53: R70 Debt Debt (Narrative) (Details) HTML 57K 24: R71 Repurchases of Common Stock (Details) HTML 47K 76: R72 Income Taxes (Details) HTML 30K 92: R73 Accumulated Other Comprehensive Income (Schedule HTML 57K Of AOCI) (Details) 52: R74 Accumulated Other Comprehensive Income (Schedule HTML 42K of Reclassifications out of AOCI) (Details) 23: R75 Earnings Per Share (Schedule Of Reconciliation Of HTML 38K Shares Outstanding For Basic And Diluted Earnings Per Share) (Details) 75: R76 Earnings Per Share (Schedule Of Number Of HTML 34K Anti-Dilutive Stock Options) (Details) 91: R77 Segment Reporting - Allocated Costs (Details) HTML 73K 55: R78 Segment Reporting - Summary of Segment Performance HTML 68K (Details) 18: R79 Fair Value Measurements (Narrative) (Details) HTML 33K 54: R80 Fair Value Measurements (Schedule of Assets and HTML 73K Liabilities) (Details) 25: R81 Hedging Instruments (Narrative) (Details) HTML 61K 77: R82 Hedging Instruments (Derivatives Designated In HTML 35K Cash Flow Hedging Relationships) (Details) 93: R83 Hedging Instruments (Schedule Of Fair Values And HTML 66K Balance Sheet Classifications Of Derivatives Designated As Hedging Instruments) (Details) 50: R84 Subsequent Events (Details) HTML 39K 34: XML IDEA XML File -- Filing Summary XML 187K 19: XML XBRL Instance -- idxx2020q110-q_htm XML 2.35M 33: EXCEL IDEA Workbook of Financial Reports XLSX 98K 9: EX-101.CAL XBRL Calculations -- idxx-20200331_cal XML 269K 10: EX-101.DEF XBRL Definitions -- idxx-20200331_def XML 631K 11: EX-101.LAB XBRL Labels -- idxx-20200331_lab XML 1.57M 12: EX-101.PRE XBRL Presentations -- idxx-20200331_pre XML 1.00M 8: EX-101.SCH XBRL Schema -- idxx-20200331 XSD 172K 44: JSON XBRL Instance as JSON Data -- MetaLinks 370± 540K 82: ZIP XBRL Zipped Folder -- 0000874716-20-000018-xbrl Zip 306K

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED BY

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the report on Form 10-Q of IDEXX Laboratories, Inc. (the “Company”) for the quarter ended March 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned certifies, pursuant to 18 U.S.C. Section 1350, as adopted by Section 906 of the Sarbanes-Oxley Act of 2002, that:


(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and


(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



	/s/ *Jonathan J. Mazelsky*
April 30, 2020	Jonathan J. Mazelsky President and Chief Executive Officer

A signed original of this written statement required by Section 906, has been provided to IDEXX Laboratories, Inc. and will be retained by IDEXX Laboratories, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

This ‘10-Q’ Filing

Date

Other Filings

Filed on:

4/30/20

8-K

For Period end:

3/31/20

List all Filings

As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/22/24 IDEXX Laboratories, Inc. 10-K 12/31/23 140:15M 2/16/23 IDEXX Laboratories, Inc. 10-K 12/31/22 136:15M 2/16/22 IDEXX Laboratories, Inc. 10-K 12/31/21 151:18M 2/12/21 IDEXX Laboratories, Inc. 10-K 12/31/20 131:15M

Idexx Laboratories Inc/DE – ‘10-Q’ for 3/31/20 – ‘EX-32.1’

On: Thursday, 4/30/20, at 5:27pm ET · For: 3/31/20 · Accession #: 874716-20-18 · File #: 0-19271

Previous ‘10-Q’: ‘10-Q’ on 10/31/19 for 9/30/19 · Next: ‘10-Q’ on 7/31/20 for 6/30/20 · Latest: ‘10-Q’ on 5/1/24 for 3/31/24 · 4 References:

Quarterly Report — Form 10-Q — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

‘EX-32.1’ — Certification — §906 – SOA’02

This Exhibit is an HTML Document rendered as filed. [ Alternative Formats ]

Dates Referenced Herein and Documents Incorporated by Reference

4 Subsequent Filings that Reference this Filing

Idexx Laboratories Inc/DE – ‘10-Q’ for 3/31/20 – ‘EX-32.1’

On: Thursday, 4/30/20, at 5:27pm ET · For: 3/31/20 · Accession #: 874716-20-18 · File #: 0-19271

Quarterly Report — Form 10-Q — Sect. 13 / 15(d) – SEA’34Filing Table of Contents

‘EX-32.1’ — Certification — §906 – SOA’02

This Exhibit is an HTML Document rendered as filed. [ Alternative Formats ]

Dates Referenced Herein and Documents Incorporated by Reference

4 Subsequent Filings that Reference this Filing

Quarterly Report — Form 10-Q — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents